Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Bioorg Med Chem. 2008 Oct 14;16(23):10022–10028. doi: 10.1016/j.bmc.2008.10.024

Figure 7.

Figure 7

A. Lissoclinidine B (5) selectively kills cells expressing wild-type p53. p53-deficient (A9) or wild-type p53 (C8) MEFs were treated with 5–20 µM 5 for 20 h. Cell death was measured by trypan blue exclusion. Data represents average and standard deviation of three independent experiments. B. Lissoclinidine B (5) induces apoptosis in C8 cells. A9 and C8 cells were incubated with 5–20 µM 5 for 14 h. Cellular PARP and β-actin were evaluated by immunoblotting using anti-PARP and anti-β-actin specific antibodies.